FDA/Hill meeting on epileptic drugs
Executive Summary
Rep. Henry Waxman (D-Calif.) and Rep. Tony Coelho (D-Calif.) met with FDA Commissioner Young and Office of Drug Standards Director Peter Rheinstein, MD, on Sept. 30 to discuss concerns over the safety of epileptic drugs. Reportedly, the congressmen emphasized the need for agency caution in regulating epilepsy products. The meeting follows closely on the heels of recent anti-epilepsy drug recalls, including a Class II recall of 50 mil. carbamazepine tablets manufactured by Pharmaceutical Basics Inc.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.